Clinical Trial Search

Primary: Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12) — 98.6; 95.8 percentage of participants — p=0.002

Primary: Incidence of Adverse Events — 28 Participants

Primary: ß-cell Response Measured by Hyperglycemic Clamp — 4.82; 4.18; 6.92; 5.95 nmol/L — p=>0.05

Primary: Our Primary Outcome for the Proposal Will be 30 Day Mortality — 53; 89 Participants

Primary: Change in Total IPSS Scores (International Prostate Symptome Score) After 1, 3, 6 and 12 Months Compared to Baseline. — -1.3; -0.6; -2.3; -1.5 Scores on a scale — p=0.0005

Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) — 100 percentage of participants

Primary: The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death — 379; 448; 496 Participants — p=0.00004

Primary: Clinical Response at Test of Cure (TOC) — 86.2; 80.0; 0.0; 6.9 Percentage of participants

Primary: Number of Participants With Contraceptive Implant Continuation at Six Months Postpartum — 15; 7 Participants

Primary: Number of Participants With Clinical and Serological Cure — 68; 61 Participants

Primary: Number of Participants Enrolled Within One Year — 12; 11 Participants

Primary: Percentage of Participants With Complete Resolution of Actinic Keratosis (AK) — 21.4; 3.4 percentage of participants — p=<0.001

Primary: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment — 8.6; 5.6 months — p=<0.0001

Primary: Percentage of Participants With Disease Progression as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)…

Primary: Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event (TEAE) During the Treatment Period (Maximum 96 Weeks) — 26; 45; 25; 51 Participants